Granted Patent
B2
US 12,195,559 · App. 18/094,167 · Granted Jan 14, 2025
CDCA1-derived peptide and vaccine containing same
Assignee:
ONCOTHERAPY SCIENCE, INC.
C07K7/06A61K35/15A61K35/17A61K39/00A61K39/001149A61K39/4611A61K39/4615A61K39/4622A61K39/464449A61P35/00C07K14/70539C12N5/0639A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
Claims (31)
1. A method of treating cancer and/or preventing postoperative recurrence thereof in a subject having a homozygous positive for-HLA-A01, which comprises administering to the subject at least one ingredient selected from the group consisting of (a) to (e) below:
(a) one or more types of peptides;
(b) one or more types of polynucleotides encoding one or more types of peptides in an expressible form;
(c) an antigen-presenting cell (APC) that presents on its cell surface a complex of a peptide and an HLA;
(d) an exosome that presents on its cell surface a complex of a peptide; and
(e) a CTL that targets a peptide;
wherein the peptide or each of the one or more types of peptides is a CDCA1-derived HLA-A01-restricted peptide having cytotoxic T cell (CTL)-inducing ability, which consists of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 8, 10, 13, 25, 33 to 35 and 37.
2. A method of treating a cancer expressing CDCA1 and HLA-A01 in a subject having a homozygous HLA-A01 in need of the cancer treatment, wherein the method comprises the steps below:
(i) measuring the level of CDCA1 expression in a biological sample collected from the diseased site of a subject with cancer;
(ii) identifying a subject with CDCA1-overexpressing cancer based on the CDCA1 expression level measured in (i); and
(iii) administering to the subject with CDCA1-overexpressing cancer as compared to normal control at least one ingredient selected from the group consisting of (a) to (e) below:
(a) one or more types of peptides;
(b) one or more types of polynucleotides encoding one or more types of peptides in an expressible form;
(c) an antigen-presenting cell (APC) that presents on its cell surface a complex of a peptide and an HLA;
(d) an exosome that presents on its cell surface a complex of a peptide; and
(e) a CTL that targets a peptide;
wherein the peptide or each of the one or more types of peptides is a CDCA1-derived HLA-A01-restricted peptide having cytotoxic T cell (CTL)-inducing ability, which consists of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 8, 10, 13, 25, 33 to 35 and 37.
3. A method of inducing an immune response against cancer in a subject having a homozygous HLA-A01 in need of the cancer treatment, which comprises administering to the subject at least one ingredient selected from the group consisting of (a) to (e) below:
(a) one or more types of peptides;
(b) one or more types of polynucleotides encoding one or more types of peptides in an expressible form;
(c) an antigen-presenting cell (APC) that presents on its cell surface a complex of a peptide and an HLA;
(d) an exosome that presents on its cell surface a complex of a peptide; and
(e) a CTL that targets a peptide;
wherein the peptide or each of the one or more types of peptides is a CDCA1-derived HLA-A01-restricted peptide having cytotoxic T cell (CTL)-inducing ability, which consists of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 8, 10, 13, 25, 33 to 35 and 37.
4. The method of claim 1 , wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular cancer, chronic myeloid leukemia (CML), esophagus cancer, gastric cancer, non-small-cell lung cancer, lymphoma, osteosarcoma, prostate cancer, kidney cancer, small-cell lung cancer, head and neck cancer, soft tissue cancer, and colon cancer.
5. The method of claim 1 , wherein the method further comprises a step for selecting a subject having a homozygous HLA-A01, prior to administering the ingredient.
6. The method of claim 1 , wherein the ingredient is the one or more types of peptides.
7. The method of claim 6 , wherein the one or more types of peptides is administered in combination with an adjuvant in an amount to enhance an immune response.
8. The method of claim 1 , wherein administering to the subject the at least one ingredient induces CTL in an HLA-A01 restrictive manner.
9. The method of claim 2 , wherein administering to the subject the at least one ingredient induces CTL in an HLA-A01 restrictive manner.
10. The method of claim 3 , wherein the immune response against cancer is induced in an HLA-A01 restrictive manner.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 24, 2024
From: YAMASHITA, SACHIKO; HIKICHI, TETSURO
To: ONCOTHERAPY SCIENCE, INC.
Reel/Frame 066552/0684 →
Priority Claims (1)
JP 2018-145607
· Aug 2, 2018
· national
Continuity (2)
Continuation
17264277
References Cited (158)
US 6573243B1
· Itagaki et al.
· 2003
[cited by applicant]
US 6699703B1
· Doucette-Stamm et al.
· 2004
[cited by applicant]
US 6858204B2
· Henderson et al.
· 2005
[cited by applicant]
US 7214786B2
· Kovalic et al.
· 2007
[cited by applicant]
US 7776341B2
· Belisle et al.
· 2010
[cited by applicant]
US 7943295B2
· Nakamura et al.
· 2011
[cited by applicant]
US 8598125B2
· Nishimura et al.
· 2013
[cited by applicant]
US 9387238B2
· Tsunoda et al.
· 2016
[cited by applicant]
US 9687538B2
· Nishimura et al.
· 2017
[cited by applicant]
US 20110263012A1
· Nakamura et al.
· 2011
[cited by applicant]
CN 1357006A
· 2002
[cited by applicant]
JP 2004512824A
· 2004
[cited by applicant]
JP 2011524737A
· 2011
[cited by applicant]
JP 2015529629A
· 2015
[cited by applicant]
RU 2560431C2
· 2015
[cited by applicant]
WO 200078806A1
· 2000
[cited by applicant]
WO 200122920A2
· 2001
[cited by applicant]
WO 200204514A2
· 2002
[cited by applicant]
WO 2002094981A2
· 2002
[cited by applicant]
WO 2003025010A2
· 2003
[cited by applicant]
WO 2003037267A2
· 2003
[cited by applicant]
WO 2004024766A2
· 2004
[cited by applicant]
WO 2004031413A2
· 2004
[cited by applicant]
WO 2004067023A2
· 2004
[cited by applicant]
WO 2004080148A2
· 2004
[cited by applicant]
WO 2005016962A2
· 2005
[cited by applicant]
WO 2005028676A2
· 2005
[cited by applicant]
WO 2005089735A2
· 2005
[cited by applicant]
WO 2006085684A2
· 2006
[cited by applicant]
WO 2007013480A2
· 2007
[cited by applicant]
WO 2007013665A2
· 2007
[cited by applicant]
WO 2007013671A2
· 2007
[cited by applicant]
WO 2009025117A1
· 2009
[cited by applicant]
WO 2009153992A1
· 2009
[cited by applicant]
WO 2010037395A2
· 2010
[cited by applicant]
WO 2010095428A1
· 2010
[cited by applicant]
WO 2014010229A1
· 2014
[cited by applicant]
WO 2016021506A1
· 2016
[cited by applicant]
WO 2016021508A1
· 2016
[cited by applicant]
WO 2017026503A1
· 2017
[cited by applicant]
WO 2017061523A1
· 2017
[cited by applicant]
“Database Printout: Database IBIS GSP, AAG74867”, Integrated Biotechnological Information Services, Sep. 3, 2001, pp. 1-2.
[cited by applicant]
“Mannide Monooleate”, Biosynth, Available Online at: https://www.biosynth.com/p/MM30170/9049-98-3-mannide-monooleate, 2022.
[cited by applicant]
“Mineral Oils, Untreated or Mildly Treated”, NCBI Bookshelf, 2022, 15 pages.
[cited by applicant]
“Sequence 166 from U.S. Pat. No. 6,867,283”, Database Genbank: AAY06266.1, Apr. 2005, 1 page.
[cited by applicant]
U.S. Appl. No. 17/264,277 , Final Office Action, Mailed On Oct. 7, 2022, 23 pages.
[cited by applicant]
U.S. Appl. No. 17/264,277 , Non-Final Office Action, Mailed On May 12, 2022, 23 pages.
[cited by applicant]
Adams et al., “Prediction of Binding to MHC Class 1 Molecules”, Journal of Immunological Methods, vol. 185, No. 2, Sep. 25, 1995, pp. 181-190.
[cited by applicant]
Anderson , “Human Gene Therapy”, Nature, vol. 392, Apr. 30, 1998, pp. 25-30.
[cited by applicant]
Belli et al., “Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings”, Journal of Clinical Oncology, vol. 20, No. 20, Oct.…
[cited by applicant]
Berger et al., “Circulation and Homing of Melanoma-Reactive T Cells to Both Cutaneous and Visceral Metastases After Vaccination With Monocyte-Derived Dendritic Cells”, International Journal of Cancer, vol. 111, No. 2, A…
[cited by applicant]
Bodey et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy”, Anticancer Research, vol. 20, No. 4, Jul. 1, 2000, pp. 2665-2674.
[cited by applicant]
Boon et al., “Human T Cell Responses Against Melanoma”, Annual Review of Immunology, vol. 24, Apr. 2006, pp. 175-208.
[cited by applicant]
Boon et al., “Human Tumor Antigens Recognized by T Lymphocytes”, Journal of Experimental Medicine, vol. 183, No. 3, Mar. 1996, pp. 725-729.
[cited by applicant]
Boon , “Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy”, International Journal of Cancer, vol. 54, No. 2, May 8, 1993, pp. 177-180.
[cited by applicant]
Bork , “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”, Genome Research, vol. 10, No. 4, Apr. 2000, pp. 398-400.
[cited by applicant]
Butterfield et al., “Generation of Human T-Cell Responses to an HLA-A2.1-Restricted Peptide Epitope Derived From α-Fetoprotein”, Cancer Research, vol. 59, No. 13, Jul. 1, 1999, pp. 3134-3142.
[cited by applicant]
Cao et al., “Analysis of the Frequencies of HLA-A, B, and C Alleles and Haplotypes in the Five Major Ethnic Groups of the United States Reveals High Levels of Diversity in these Loci and Contrasting Distribution Pattern…
[cited by applicant]
Celis , “Getting Peptide Vaccines to Work: Just a Matter of Quality Control?”, Journal of Clinical Investigation, vol. 110, No. 12, Dec. 15, 2002, pp. 1765-1768.
[cited by applicant]
Celis et al., “Identification of Potential CTL Epitopes of Tumor-Associated Antigen MAGE-1 for Five Common HLA-A Alleles”, Molecular Immunology, vol. 31, No. 18, Dec. 1994, pp. 1423-1430.
[cited by applicant]
Chujoh et al., “The Role of Anchor Residues in the Binding of Peptides to HLA-A 1101 Molecules”, Tissue Antigens, vol. 52, No. 6, Dec. 1998, pp. 501-509.
[cited by applicant]
Coulie et al., “Cytolytic T-cell Responses of Cancer Patients Vaccinated With a MAGE Antigen”, Immunological Reviews, vol. 188, Oct. 2002, pp. 33-42.
[cited by applicant]
Crystal , “Transfer of Genes to Humans: Early Lessons and Obstacles to Success”, Science, vol. 270, No. 5235, Oct. 20, 1995, pp. 404-410.
[cited by applicant]
Dermer , “Another Anniversary for the War on Cancer”, Biotechnology, vol. 12, Mar. 1994, p. 320.
[cited by applicant]
Dionne et al., “Functional Characterization of CTL Against gp100 Altered Peptide Ligands”, Cancer Immunology, Immunotherapy, vol. 52, No. 4, Feb. 18, 2003, pp. 199-206.
[cited by applicant]
Dionne et al., “Her-2/Neu Altered Peptide Ligand-Induced CTL Responses: Implications for Peptides With Increased HLA Affinity and T-Cell-Receptor Interaction”, Cancer Immunology Immunotherapy, vol. 53, No. 4, Apr. 2004,…
[cited by applicant]
Doerks et al., “Protein Annotation: Detective Work for Function Prediction”, Trends in Genetics, vol. 14, No. 6, Jun. 1998, pp. 248-250.
[cited by applicant]
Eck et al., “Gene-Based Therapy”, The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ninth Edition, 1996, pp. 77-101.
[cited by applicant]
Engelhard , “Structure of Peptides Associated With MHC Class I Molecules”, Current Opinion in Immunology vol. 6, No. 1, Feb. 1994, pp. 13-23.
[cited by applicant]
Ezzell et al., “Cancer “Vaccines”: An Idea Whose Time Has Come?”, Journal of NIH Research, vol. 7, Jan. 1995, pp. 46-49.
[cited by applicant]
Falk et al., “Allele-Specific Motifs Revealed by Sequencing of Self-Peptides Eluted from MHC Molecules”, Nature, vol. 351, No. 6324, May 23, 1991, pp. 290-296.
[cited by applicant]
Falk et al., “Peptide Motifs of HLA-A1, -A11, -A31, and -A33 Molecules”, Immunogenetics, vol. 40, No. 3, 1994, pp. 238-241.
[cited by applicant]
Fournier et al., “Randomized Clinical Studies of Anti-Tumor Vaccination: State of the Art in 2008”, Expert Review of Vaccines, vol. 8, No. 1, Jan. 2009, pp. 51-66.
[cited by applicant]
Freshney , “Culture of Animal Cells”, A Manual of Basic Technique, 1983, 4 pages.
[cited by applicant]
Fujie et al., “A MAGE-1-Encoded HLA-A24-Binding Synthetic Peptide Induces Specific Anti-Tumor Cytotoxic T Lymphocytes”, International Journal of Cancer, vol. 80, No. 2, Jan. 18, 1999, pp. 169-172.
[cited by applicant]
Gambacorti-Passerini et al., “Mapping of HLA Class I Binding Motifs in Forty-Four Fusion Proteins Involved in Human Cancers”, Clinical Cancer Research, vol. 3, No. 5, May 1997, pp. 675-683.
[cited by applicant]
Gao et al., “Tumor Vaccination That Enhances Antitumor T-cell Responses Does Not Inhibit the Growth of Established Tumors Even in Combination With Interleukin-12 Treatment: The Importance of Inducing Intratumoral T-cell…
[cited by applicant]
Guo et al., “Different Length Peptides Bind to HLA-Aw68 Similarly at Their Ends but Bulge Out in the Middle”, Nature, vol. 360, No. 6402, Nov. 1992, pp. 364-366.
[cited by applicant]
Gura , “Systems for Identifying New Drugs are Often Faulty”, Science, Cancer Models, vol. 278, No. 5340, Nov. 7, 1997, pp. 1041-1042.
[cited by applicant]
Harao et al., “CDCA1, A Novel Cancer-Testis Antigen Useful for Immunotherapy of Lung Cancer”, Nihon Gangakkaisokai, vol. 66, 2007, 3 pages.
[cited by applicant]
Harao et al., “Cell Division Cycle Associated 1, an Ideal Lung Cancer Antigen for Immunotherapy, Identified Using cDNA Microarray Analysis”, Doctor's Thesis, 2008, pp. 1-49.
[cited by applicant]
Harao et al., “Development of Cancer Immunotherapy Targeting a Novel Cancer-Testis Antigen, CDCA1, That Highly Expresses in Lung Cancer”, Kibangakutekimennekikenkyuukai sokai; 2008, 4 Pages.
[cited by applicant]
Harao et al., “HLA-A2-restricted CTL Epitopes of a Novel Lung Cancer-Associated Cancer Testis Antigen, Cell Division Cycle Associated 1, Can Induce Tumor-Reactive CTL”, International Journal of Cancer, vol. 123, No. 11,…
[cited by applicant]
Harao et al., “Identification of a Novel Cancer-Testis Antigen, CDCA1, That is Useful for Immunotherapy for Lung Cancer”, Nihon Gekagakkai, 2008, 3 pages.
[cited by applicant]
Harris , “Structure and Function of the p53 Tumor Suppressor Gene: Clues for Rational Cancer Therapeutic Strategies”, Journal of the National Cancer Institute, vol. 88, No. 20, Oct. 16, 1996, pp. 1442-1455.
[cited by applicant]
Hayama et al., “Activation of CDCA1-KNTC2, Members of Centromere Protein Complex, Involved in Pulmonary Carcinogenesis”, Cancer Research, vol. 61, No. 22, Nov. 1, 2006, pp. 10339-10348.
[cited by applicant]
Hoffmann et al., “The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-type Sequence P53264-272 Epitope”, Journal of Immunology, vol. 168, No. 3, Feb. 1, 2002, pp. 1338-1347.
[cited by applicant]
Hoof et al., “NetMHCpan, a Method for MHC Class I Binding Prediction Beyond Humans”, Immunogenetics, vol. 61, No. 1, Jan. 2009, pp. 1-13.
[cited by applicant]
Ishizaki et al., “Inhibition of Tumor Growth With Antiangiogenic Cancer Vaccine Using Epitope Peptides Derived From Human Vascular Endothelial Growth Factor Receptor 1”, Clinical Cancer Research, vol. 12, No. 9, Oct. 1,…
[cited by applicant]
Jain , “Barriers to Drug Delivery in Solid Tumors”, Scientific American, vol. 271, No. 1, Jul. 1994, pp. 58-65.
[cited by applicant]
Johnson , “The Clinical Impact of Screening and Other Experimental Tumor Studies”, Cancer Treatment Reviews, vol. 2, No. 1, Mar. 1975, pp. 1-31.
[cited by applicant]
Juengst , “What Next for Human Gene Therapy?”, British Medical Journal, vol. 326, Jun. 28, 2003, pp. 1410-1411.
[cited by applicant]
Karin et al., “Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Gamma and Tumor Necrosis Factor…
[cited by applicant]
Kast et al., “Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins”, Journal of Immunology, vol. 152, No. 8, Apr. 15, 1994, pp. 3904-3912.
[cited by applicant]
Kikuchi et al., “Identification of a SART-1-Derived Peptide Capable of Inducing HLA-A24-Restricted and Tumor-Specific Cytotoxic T Lymphocytes”, International Journal of Cancer, vol. 81, No. 3, May 5, 1999, pp. 459-466.
[cited by applicant]
Klebanoff et al., “Therapeutic Cancer Vaccines: Are We There Yet?”, Immunological Reviews, vol. 239, No. 1, Jan. 2011, pp. 27-44.
[cited by applicant]
Kondo et al., “Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class 1 Molecules”, Journal of Immunology, vol. 155, No. 9, Nov. 1, 1995, pp. 4307-4312.
[cited by applicant]
Kubo et al., “Definition of Specific Peptide Motifs for Four Major HLA-A Alleles”, Journal of Immunology, vol. 152, No. 8, Apr. 15, 1994, pp. 3913-3924.
[cited by applicant]
Liu et al., “Human NUF2 Interacts With Centromere-Associated Protein E and is Essential for a Stable Spindle Microtubule-kinetochore Attachment”, The Journal of Biological Chemistry, vol. 282, No. 29, Jul. 20, 2007, pp.…
[cited by applicant]
Marchand et al., “Biological and Clinical Developments in Melanoma Vaccines”, Expert Opinion on Biological Therapy , vol. 1, No. 3, May 2001, pp. 497-510.
[cited by applicant]
Marchand et al., “Tumor Regressions Observed in Patients With Metastatic Melanoma Treated With an Antigenic Peptide Encoded By Gene MAGE-3 And Presented by HLA-A1”, International Journal of Cancer, vol. 80, No. 2, Jan. …
[cited by applicant]
Marshall , “Gene Therapy's Growing Pains”, Science, vol. 269, No. 5227, Aug. 25, 1995, pp. 1050-1055.
[cited by applicant]
Morel et al., “Processing of Some Antigens by the Standard Proteasome but Not by the Immunoproteasome Results in Poor Presentation by Dendritic Cells”, Immunity, vol. 12, No. 1, Jan. 2000, pp. 107-117.
[cited by applicant]
Nabetani et al., “A Conserved Protein, Nuf2, is Implicated in Connecting the Centromere to the Spindle During Chromosome Segregation: A Link Between the Kinetochore Function and the Spindle Checkpoint”, Chromosoma, vol.…
[cited by applicant]
Nielsen et al., “Improved Prediction of MHC Class I and Class II Epitopes Using a Novel Gibbs Sampling Approach”, Bioinformatics, vol. 20, No. 9, Jun. 12, 2004, pp. 1388-1397.
[cited by applicant]
Nielsen et al., “Reliable Prediction of T-Cell Epitopes Using Neural Networks With Novel Sequence Representations”, Protein Science, vol. 12, No. 5, May 2003, pp. 1007-1017.
[cited by applicant]
Obara et al., “Phase I Clinical Trial of Cell Division Associated 1 (CDCA1) Peptide Vaccination For Castration Resistant Prostate Cancer”, Cancer Science, vol. 108, No. 7, Jul. 2017, pp. 1452-1457.
[cited by applicant]
Ochoa-Garay et al., “The Ability of Peptides to Induce Cytotoxic T Cells in Vitro does not Strongly Correlate with their Affinity for the H-2Ld Molecule: Implications for Vaccine Design and Immunotherapy”, Molecular Imm…
[cited by applicant]
Oiso et al., “A Newly Identified MAGE-3-Derived Epitope Recognized by HLA-A24-Restricted Cytotoxic T Lymphocytes”, International Journal of Cancer, vol. 81, No. 3, May 5, 1999, pp. 387-394.
[cited by applicant]
Parker et al., “Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains”, Journal of Immunology, vol. 152, No. 1, Jan. 1, 1994, pp. 163-175.
[cited by applicant]
Application No. PCT/JP2019/030117 , International Search Report and Written Opinion, Mailed On Oct. 15, 2019, 22 pages.
[cited by applicant]
Pearson , “An Introduction to Sequence Similarity (“Homology”) Searching”, Current Protocols in Bioinformatics, vol. 42, No. 1, Jun. 2013, pp. 1-9.
[cited by applicant]
Rammensee et al., “MHC Ligands and Peptide Motifs: First Listing”, Immunogenetics, vol. 41, No. 4, Feb. 1995, pp. 178-228.
[cited by applicant]
Rosenberg et al., “Cancer Immunotherapy: Moving Beyond Current Vaccines”, Nature Medicine, vol. 10, No. 9, Sep. 2004, pp. 909-915.
[cited by applicant]
Ross et al., “Gene Therapy in the United States: A Five-Year Status Report”, Human Gene Therapy, vol. 7, No. 14, Sep. 10, 1996, pp. 1781-1790.
[cited by applicant]
Rubanyi , “The Future of Human Gene Therapy”, Molecular Aspects of Medicine, vol. 22, No. 3, Jun. 2001, pp. 113-142.
[cited by applicant]
Schreiber et al., “Tumor Immunogenicity and Responsiveness to Cancer Vaccine Therapy; The State of the Art”, Seminars in Immunology, vol. 22, No. 3, Jun. 2010, pp. 105-112.
[cited by applicant]
Schueler-Furman et al., “Structure-Based Prediction of Binding Peptides to MHC Class I Molecules: Application to a Broad Range of MHC Alleles”, Cambridge University Press, Protein Science, vol. 9, No. 9, Sep. 2000, pp. …
[cited by applicant]
Sette et al., “Nine Major HLA Class I Supertypes Account for the Vast Preponderance of HLA-A and -B Polymorphism”, Immunogenetics, vol. 50, Nos. 3-4, Nov. 1999, pp. 201-212.
[cited by applicant]
Shastri et al., “Presentation of Endogenous Peptide/MHC Class I Complexes is Profoundly Influenced by Specific C-Terminal Flanking Residues.”, The Journal of Immunology, vol. 155, No. 9, Nov. 1, 1995, pp. 4339-4346.
[cited by applicant]
Sidney et al., “Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertoires of Common HLA Molecules”, Human Immunology, vol. 45, No. 2, Feb. 1996, pp. 79-93.
[cited by applicant]
Sidney et al., “HLA Class 1 Supertypes: A Revised and Updated Classification”, BMC Immunology, vol. 9, No. 1, Jan. 22, 2008, 15 pages.
[cited by applicant]
Spitler , “Cancer Vaccines: The Interferon Analogy”, Cancer Biotherapy, vol. 10, No. 1, 1995, pp. 1-3.
[cited by applicant]
Stills , “Adjuvants and Antibody Production: Dispelling the Myths Associated with Freund's Complete and Other Adjuvants”, ILAR journal, vol. 46, No. 3, 2005, pp. 280-293.
[cited by applicant]
Takiguchi et al., “Analysis of Three HLA-A*3303 Binding Peptide Anchors Using an HLA-A*3303 Stabilization Assay”, Tissue Antigens, vol. 55, No. 4, Apr. 2000, pp. 296-302.
[cited by applicant]
Tanaka et al., “Induction of Antitumor Cytotoxic T Lymphocytes With a MAGE-3-Encoded Synthetic Peptide Presented by Human Leukocytes Antigen-A24”, Cancer Research, vol. 57, No. 20, Oct. 15, 1997, pp. 4465-4468.
[cited by applicant]
Tokuriki et al., “Stability Effects of Mutations and Protein Evolvability”, Current Opinion in Structural Biology, vol. 19, No. 5, Oct. 2009, pp. 596-604.
[cited by applicant]
Van Der Burg et al., “Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability”, Journal of Immunology, vol. 156, No. 9, May 1, 1996, pp. 3308-3314.
[cited by applicant]
Verma et al., “Gene Therapy—Promises, Problems and Prospects”, Nature, vol. 389, No. 6648, Sep. 18, 1997, pp. 239-242.
[cited by applicant]
Vissers et al., “The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocyte”, Cancer Research, American Association for Cancer R…
[cited by applicant]
Walker , “Drug Target Discovery by Gene Expression Analysis: Cell Cycle Genes”, Current Cancer Drug Targets, vol. 1, No. 1, May 2001, pp. 73-83.
[cited by applicant]
Wells , “Additivity of Mutational Effects in Protein”, Biochemistry, vol. 29, No. 37, Sep. 18, 1990, pp. 8509-8517.
[cited by applicant]
Wigge et al., “The Ndc80p Complex From
[cited by applicant]
Zaremba et al., “Identification of an Enhancer Agonist Cytotoxic T Lymphocyte Peptide From Human Carcinoembryonic Antigen”, Cancer Research, vol. 57, No. 20, Oct. 15, 1997, pp. 4570-4577.
[cited by applicant]
Zips et al., “New Anticancer Agents: In Vitro and In Vivo Evaluation”, In Vivo, vol. 19, No. 1, Jan. 2005, pp. 1-7.
[cited by applicant]
Harao, “Cell Division Cycle Associated 1, an Ideal Lung Cancer Antigen for Immunotherapy, Identified Using cDNA Microarray Analysis”, Doctor's Thesis, 2008, pp. 1-49.
[cited by applicant]
Hayama et al., “Activation of CDCA1-KNTC2, Members of Centromere Protein Complex, Involved in Pulmonary Carcinogenesis”, Cancer Res. Nov. 1, 2006;66(21):10339-48.
[cited by applicant]
Ishizaki et al., “Inhibition of Tumor Growth With Antiangiogenic Cancer Vaccine Using Epitope Peptides Derived From Human Vascular Endothelial Growth Factor Receptor 1”, Clin Cancer Res. Oct. 1, 2006;12(19):5841-9.
[cited by applicant]
Johnson et al., “The Clinical Impact of Screening and Other Experimental Tumor Studies”, Cancer Treatment Reviews, vol. 2, No. 1, Mar. 1975, pp. 1-31.
[cited by applicant]
Filippovich et al., “Biochemical Bases of Human Life”, Textbook for Higher Educational Institutions; Moscow, Vlados, 2005, 407; 49-50, 70.
[cited by applicant]
Lee et al., “Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression”, J. Immunol., Dec. 1, 1999…
[cited by applicant]
Pakula et al., “Genetic Analysis of Protein Stability and Function”, Annu. Rev. Genet., 1989; 23:289-310.
[cited by applicant]
Seliverstov et al., “Spinal Muscular Atrophies: Concept, Differential Diagnosis, Treatment Prospects”, Nervnye bolenzni, 2015; 3:9-17.
[cited by applicant]